肿瘤细胞治疗研究
ALL SOURCES
Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.
同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号，增强 CAR-NK 细胞对难治性实体瘤的疗效。
Breaking the barrier: Synergistic 2B4.4-1BB signaling potentiates HER2-CAR NK cells to penetrate and destroy ADCC-resistant tumors.
Depletion of IL-10 in CAR-NK cells augments reprogramming of the tumor microenvironment and ameliorates therapeutic efficacy.
我们的研究结果表明，抑制 IL-10 分泌可增强 CAR 工程化 NK-92 细胞的治疗潜力，提示这一策略有望成为临床转化的有前景途径。
ErbB2/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression.
嵌合抗原受体工程化 NK 细胞在过继性肿瘤免疫治疗中展现出前景。
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.
HER2 扩增见于约 5% 的结直肠癌（CRC）病例，且仅部分与联合人表皮生长因子受体 2（HER2）/表皮生长因子受体（EGFR）靶向治疗的临床应答相关。
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
乳腺癌细胞上 ICAM-1 的下调是逃逸 trastuzumab 触发的 ADCC 的关键机制。相反，CAR-NK 细胞能够克服由 ICAM-1 减少引起的癌细胞耐药，凸显了 CAR-NK 细胞在肿瘤免疫治疗中的潜力。
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma.
颅内注射 HER2 靶向 CAR-NK 细胞在复发性 GB 患者中是可行且安全的。1 108 个 NK-92/5.28.z 细胞被确定为后续扩展队列重复局部注射 CAR-NK 细胞的最大可行剂量。
Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence.
综合来看，我们的研究表明，肝细胞癌衰老的异质性但选择性特征可被不同的免疫治疗策略加以利用。
CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma.
该联合治疗逆转了免疫抑制性肿瘤微环境，T 细胞和 NKT 细胞浸润增加。
Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies.
乳腺癌仍是全球癌症相关发病率和死亡率的主要原因，其治疗反应受每种乳腺癌亚型独特生物学特征的影响。
MEMBER ACCOUNT
登录成功会直接打开下一页。
